Canada Pension Plan Investment Board Makes New $240.91 Million Investment in IQVIA Holdings Inc. $IQV

Key Points

• Canada Pension Plan Investment Board acquired 1.25 million IQVIA shares worth approximately $240.9 million in the second quarter, giving it a 0.76% stake. Institutional investors now own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in earnings per share and $4.37 billion in revenue, with revenue rising 8.7% year over year. The company also authorized a $2 billion share-repurchase program.
• Analysts remain generally positive, with a consensus “Moderate Buy” rating and a $241.88 price target, although IQV shares recently traded near their 12-month high at $259.97. Several insiders have sold shares during the past 90 days.

Canada Pension Plan Investment Board bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,246,820 shares of the medical research company's stock, valued at approximately $240,911,000. Canada Pension Plan Investment Board owned 0.76% of IQVIA at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Korea Investment CORP bought a new stake in IQVIA during the 2nd quarter valued at about $13,918,000. BlackRock Inc. purchased a new position in shares of IQVIA during the second quarter worth approximately $2,811,292,000. Concurrent Investment Advisors LLC raised its stake in shares of IQVIA by 36.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company's stock valued at $2,693,000 after acquiring an additional 3,161 shares in the last quarter. Focus Partners Advisor Solutions LLC purchased a new stake in shares of IQVIA in the second quarter valued at approximately $976,000. Finally, Deutsche Bank AG purchased a new stake in shares of IQVIA in the second quarter valued at approximately $143,074,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider W Richard Staub sold 5,500 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company's stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 12,913 shares of company stock valued at $3,098,793 over the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Trading Down 0.1%

Shares of NYSE:IQV opened at $259.97 on Wednesday. The company has a market capitalization of $42.79 billion, a PE ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $261.88. The business's fifty day simple moving average is $216.59 and its 200-day simple moving average is $188.02.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. During the same period in the prior year, the business posted $2.81 EPS. The firm's quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has authorized a share buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IQV. Royal Bank Of Canada lifted their target price on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. TD Cowen lifted their price objective on IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Stifel Nicolaus upped their price objective on shares of IQVIA from $220.00 to $276.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Finally, HSBC reiterated a "buy" rating and set a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $241.88.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source